BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Sacubitril/valsartan Total	Control Events	Control Total	Weight	Risk Ratio M-H, Random, 95% CI
1.4.1 English						
AWAKE-HF 2019	0	69	1	70	0.1%	0.34 [0.01, 8.16]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	1	231	1	232	0.1%	1.00 [0.06, 15.96]
OUTSTEP-HF	1	309	4	310	0.2%	0.25 [0.03, 2.23]
PARADIGM-HF 2014	729	4203	848	4229	97.9%	0.86 [0.79, 0.95]
PIONEER-HF 2018	10	440	15	441	1.3%	0.67 [0.30, 1.47]
PRIME-HF 2019	1	60	0	58	0.1%	2.90 [0.12, 69.81]
Subtotal (95% CI)		**5320**		**5348**	**99.6%**	**0.86 [0.79, 0.94]**
Total events	742		869			
Heterogeneity: Tau² = 0.00; Chi² = 2.54, df = 5 (P = 0.77); I² = 0%						
Test for overall effect: Z = 3.32 (P = 0.0009)						
1.4.2 Chinese						
Li J 2019 (1)	3	62	5	64	0.4%	0.62 [0.15, 2.48]
Subtotal (95% CI)		**62**		**64**	**0.4%**	**0.62 [0.15, 2.48]**
Total events	3		5			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.68 (P = 0.50)						
Total (95% CI)		**5382**		**5412**	**100.0%**	**0.86 [0.79, 0.94]**
Total events	745		874			
Heterogeneity: Tau² = 0.00; Chi² = 2.75, df = 6 (P = 0.84); I² = 0%						
Test for overall effect: Z = 3.36 (P = 0.0008)						
Test for subgroup differences: Chi² = 0.22, df = 1 (P = 0.64), I² = 0%